Drugs / GSK1004723
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00694993 | Dec 2007 → May 2008 | seasonal allergic rhinitis | GlaxoSmithKline | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT00972504 Comparator | Jun → Aug 2009 | seasonal allergic rhinitis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00824356 Comparator | Jun → Aug 2008 | allergic rhinitis | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK1004723 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00824356 ↗ |
| Action | Inhibit | “Histamine H3 receptor antagonist” CHEMBL1767164 ↗ |
| Modality | Small molecule | — CHEMBL1767164 ↗ |
| Route | Intranasal | “intranasal spray administration” NCT00694993 ↗ |
| Target | HRH1 | “Histamine H1 receptor antagonist” CHEMBL1767164 ↗ |
| Target | HRH3 | “Histamine H3 receptor antagonist” CHEMBL1767164 ↗ |